Vaxcyte director granted RSUs and stock options

Vaxcyte, Inc. director Lee Jacks reported equity awards consisting of restricted stock units and stock options.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Vaxcyte, Inc. director Lee Jacks reported equity awards consisting of restricted stock units and stock options. He received 2,265 RSUs, each representing one share of common stock, and 11,389 stock options with an exercise price of $49.5600 per share.

The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual stockholder meeting, subject to acceleration and his continuous service. The stock options vest monthly on the same overall schedule and expire on June 15, 2036. Following the grant, Jacks directly holds 6,856 shares of common stock, plus the newly granted options.

Insider Trade Summary

Grant/Award: 13,654 shares

Grant/Award 2 txns

Insider Lee Jacks

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	11,389	$0.00	$0.00
Grant/Award	Common Stock	2,265	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 11,389 contracts (Direct); Common Stock — 6,856 shares (Direct)

Footnotes (2)

F1. Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.
F2. The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.

Key Figures

RSUs granted: 2,265 units Options granted: 11,389 options Option exercise price: $49.5600 per share +2 more

5 metrics

RSUs granted 2,265 units Restricted stock units granted to director on June 15, 2026

Options granted 11,389 options Stock options granted to director on June 15, 2026

Option exercise price $49.5600 per share Strike price for 11,389 stock options

Option expiration June 15, 2036 Expiration date of granted stock options

Shares after RSU grant 6,856 shares Common stock directly held by Lee Jacks following grant

Key Terms

restricted stock units ("RSUs"), Stock Option (right to buy), contingent right, continuous service

4 terms

restricted stock units ("RSUs") financial

"Represents the number of shares of Common Stock underlying restricted stock units ("RSUs")."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Stock Option (right to buy) financial

"Stock Option (right to buy) with an exercise price of 49.5600."

contingent right financial

"Each RSU represents the contingent right to receive one share of the Issuer's Common Stock."

continuous service financial

"subject to the Reporting Person's continuous service through such date."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Vaxcyte (PCVX) director Lee Jacks report in this Form 4?

Director Lee Jacks reported receiving equity compensation awards from Vaxcyte. The filing shows grants of restricted stock units and stock options, increasing his direct common stock holdings and adding a new option position tied to future vesting.

How many Vaxcyte (PCVX) RSUs were granted to director Lee Jacks?

Lee Jacks was granted 2,265 restricted stock units (RSUs). Each RSU equals one share of Vaxcyte common stock. The RSUs will fully vest by June 15, 2027 or the day before the next annual stockholder meeting, assuming he remains in continuous service.

What stock options did Vaxcyte (PCVX) grant to director Lee Jacks?

Vaxcyte granted Lee Jacks 11,389 stock options with an exercise price of $49.5600 per share. These options vest monthly and fully vest by June 15, 2027 or the day before the next annual stockholder meeting, and they expire on June 15, 2036.

When do Lee Jacks’ Vaxcyte (PCVX) RSUs and options fully vest?

Both the RSUs and stock options are scheduled to fully vest on the earlier of June 15, 2027 or the day prior to Vaxcyte’s next annual stockholder meeting. Vesting requires his continuous service, with options vesting monthly during the period.

How many Vaxcyte (PCVX) shares does Lee Jacks own after these grants?

After the RSU grant, Lee Jacks directly holds 6,856 shares of Vaxcyte common stock. He also holds 11,389 stock options that, once vested and exercised at the stated strike price, would deliver additional shares of common stock.

Does this Vaxcyte (PCVX) Form 4 show any stock sales by Lee Jacks?

The Form 4 does not report any stock sales by Lee Jacks. It shows two acquisition-type transactions coded “A”: a grant of 2,265 restricted stock units and a grant of 11,389 stock options as part of his director compensation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/16/2026 - 04:18 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lee Jacks

(Last)

(First)

(Middle)

C/O VAXCYTE, INC.

825 INDUSTRIAL ROAD, SUITE 300

(Street)

SAN CARLOS

CALIFORNIA

94070

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vaxcyte, Inc. [ PCVX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/15/2026		A		2,265⁽¹⁾	A	$0	6,856	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$49.56	06/15/2026		A		11,389		⁽²⁾	06/15/2036	Common Stock	11,389	$0	11,389	D

Explanation of Responses:

1. Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.

2. The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.

Remarks:

	Jacks Lee, by /s/ Peter N. Efremenko, Attorney-In-Fact	06/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR